Holen Sie sich die Stockscreener-App
26.56
10.94%
2.62
Vorhandelsmarkt:
26.95
0.39
+1.47%
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AVBP PE Ratio & Valuation, Is AVBP Overvalued - Intellectia AI
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month HighHere's What Happened - MarketBeat
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AVBP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ArriVent BioPharma, Inc. (AVBP): Investor Outlook With A Promising 73% Potential Upside - DirectorsTalk Interviews
ArriVent BioPharma (AVBP) Stock Analysis Report | Financials & Insights - Benzinga
Risk Analysis: Whats next for ArriVent BioPharma Inc stockGap Down & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ArriVent BioPharma (AVBP) Projected to Post Earnings on Monday - MarketBeat
How much upside does ArriVent BioPharma Inc. haveWeekly Loss Report & Consistent Growth Stock Picks - mfd.ru
Can ArriVent BioPharma Inc. keep up with sector leadersQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru
Is ArriVent BioPharma Inc. showing insider buyingJuly 2025 Sector Moves & Capital Efficiency Focused Strategies - mfd.ru
How (AVBP) Movements Inform Risk Allocation Models - Stock Traders Daily
Hillhouse discloses 9.5% ArriVent BioPharma (AVBP) ownership stake - Stock Titan
Insider Buy: How sensitive is ArriVent BioPharma Inc to inflationJuly 2025 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Why ArriVent BioPharma Inc. stock remains resilientDay Trade & Smart Investment Allocation Insights - mfd.ru
Does ArriVent BioPharma Inc. have a sustainable dividend2025 Biggest Moves & Long-Term Safe Investment Ideas - mfd.ru
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a Potential 79.45% Upside for Biotech Enthusiasts - DirectorsTalk Interviews
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 6.8%Still a Buy? - MarketBeat
Growth Prospects for the EGFR-NSCLC Market Analyzed - Intellectia AI
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.6%Here's Why - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Trading Systems Reacting to (AVBP) Volatility - Stock Traders Daily
Targets Report: Whats the profit margin of ArriVent BioPharma IncJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
$207B Market Shift: The Race for Fast Track Approval in Oncology - The Malaysian Reserve
$207B Market Shift: The Race for Fast Track Approval in Oncology (2026-02-05) - Seeking Alpha
Aug Catalysts: Is ASTC a play on infrastructure spending2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Breakouts Watch: Can ArriVent BioPharma Inc maintain sales growthJuly 2025 Retail & Fast Gain Stock Trading Tips - baoquankhu1.vn
Big Money Moves Out of ArriVent BioPharma - TipRanks
Is ArriVent BioPharma Inc. stock vulnerable to regulatory risks2025 Top Decliners & Long-Term Safe Return Strategies - mfd.ru
What’s next for ArriVent BioPharma Inc. stockTrade Ideas & Consistent Growth Equity Picks - mfd.ru
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Unlocking a Potential 78.81% Upside in the Biotech Sector - DirectorsTalk Interviews
How Arrivent Biopharma Inc. (AVBP) Affects Rotational Strategy Timing - Stock Traders Daily
Death Cross: Does First Commonwealth Financial Corporation offer margin of safetyEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Pullback Watch: Will FOXF benefit from green energy policiesEarnings Beat & Scalable Portfolio Growth Ideas - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5.8%Here's What Happened - MarketBeat
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
Notable Thursday Option Activity: AVBP, GRAL, APPN - Nasdaq
Street Watch: How is EZGO managing supply chain issuesMarket Volume Report & Smart Allocation Stock Tips - baoquankhu1.vn
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC - MSN
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 8.2%What's Next? - MarketBeat
Can ArriVent BioPharma Inc. stock resist market sell offs - bollywoodhelpline.com
Rate Cut: Should I trade or invest in Materialise NV Depositary ReceiptOil Prices & Stock Portfolio Risk Control - baoquankhu1.vn
Technical Analysis: Is ArriVent BioPharma Inc subject to activist investor interest2025 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Entry Recap: Will SHIP outperform tech stocksQuarterly Portfolio Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
(AVBP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 7.2%Should You Buy? - MarketBeat
Aug Drivers: Should you avoid Zura Bio Limited stock right nowEarnings Summary Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):